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SUMMARY
Objective: Treatment with carbamazepine (CBZ), a potent enzyme inducer, is known
to affect the lipid profile, steroid, and vitamin Dmetabolism. Consequently, it has been
postulated that patients on CBZ should be switched to noninducing antiepileptic drugs
(AEDs). However, little is known about the seizure outcome following a CBZ switch in
seizure-free patients. We aimed to address this issue using a controlled observational
study design.
Methods: Fifty-eight patients taking CBZ for focal epilepsy were assessed for discontin-
uing CBZ treatment due to concerns of long-term adverse-effects; 34 discontinued its
therapy and 24 continued with CBZ. Six-month seizure freedom was the primary end
point. Furthermore, serum samples (total cholesterol (TC), low-density lipoprotein
(LDL), high-density lipoprotein (HDL), triglycerides, sex hormone–binding globulin
(SHBG), free testosterone, and 25-hydroxyvitamin D levels from before and at least 3
months after discontinuation or continuation were obtained from all patients.
Results: Seizure-free patients had a 5-fold elevated odds of seizure recurrence if CBZ
was discontinued (95% confidence interval [CI 0.51–49.3; p = 0.17). A significant
decrease in serum levels of TC, LDL, HDL, and SHBG as well as a significant increase
in that of free testosterone were found in the discontinuation group compared with
those who continued CBZ. Nonsignificant changes in triglycerides and vitamin D levels
were detected.
Significance: Discontinuation of CBZ in seizure-free patients seems to carry a moder-
ate, but legitimate, risk of relapse. Conversely, our results indicate that CBZ might
have unfavorable effects on serum levels of TC, LDL, HDL, SHBG, and free testos-
terone.
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Epilepsy often requires long-term, even lifelong, treat-
ment with antiepileptic drugs (AEDs). The target of epi-
lepsy therapy is always seizure freedom with as few adverse
effects as possible. Carbamazepine (CBZ) is considered as a
drug of choice in focal epilepsy,1 although a range of well-
tolerated and effective AEDs have become available during
the past 2 decades. In addition to epilepsy, CBZ is used
widely in the treatment of neuralgic pain syndromes,
migraine, and some psychiatric indications.
CBZ is a potent inducer of the cytochrome P450
(CYP450) enzyme system.2 In addition to their well-known
effects on drug metabolism, CYP450 enzymes are also
involved in endogenous metabolic pathways,3 and can influ-
ence bone biochemistry, gonadal steroids, and cholesterol
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synthesis.4–7 Second-generation AEDs have weak or nonex-
istent inducing properties.8 To date, a reduction in total
cholesterol levels has been documented after switching
from inducing AEDs (CBZ or phenytoin) to lamotrigine,
levetiracetam, oxcarbazepine, topiramate, or zonisamide.9–
12 One major concern is that AEDs could contribute to the
pandemic of vascular disease.13 Accordingly, it has been
proposed that CBZ should not be regarded as first-line ther-
apy in newly diagnosed epilepsy.14
The impact of these potential deleterious effects of long-
term EI in those patients currently receiving CBZ therapy is
unclear, and this constitutes a significant issue in current
clinical management. If metabolic complications are
detected, they might be treated, but switching to a newer
AED may be a better option. Such alterations are often con-
sidered and implemented in clinical practice with the appre-
ciation that the switch also carries a risk of relapse. In
addition, there are a number of clinical situations requiring
a switch from CBZ to a newer AED (for example, pharma-
cotherapy for cancer). Consequently, it has been postulated
that patients being treated with EI AEDs should be switched
to noninducing AEDs.15
Here, we provide practical information related to discon-
tinuation of CBZ due to concerns about the long-term effects
of enzyme induction (EI) from 3 different viewpoints: (1) the
patient0s perspective, (2) seizure outcome, and (3) laboratory
parameters (lipids, sex hormone-binding globulin [SHBG],
testosterone, and vitamin D). The main objective was to clar-
ify the importance of these data on individual parameters,
when deciding whether to continue CBZ treatment.
Materials and methods
Patients with focal epilepsy (aged ≥18 years) treated in
Tampere University Hospital were identified from the hos-
pital patient registry on 31 December 2014 using Interna-
tional Classification of Diseases (ICD-10) diagnostic codes
for focal and unclassifiable focal epilepsy (G40.1X,
G40.2X and G40.9). In addition, patients from Sein€ajoki
Central Hospital and Vaasa Central Hospital were identi-
fied. We included patients who were currently being trea-
ted with CBZ (monotherapy or polytherapy) and whose
treating epileptologist had been considering whether to dis-
continue CBZ due to concerns about the long-term effects
linked with EI. This situation was defined as the baseline.
Those who were switched from CBZ to some other AED
due to unsatisfactory seizure control, adverse events, drug
interactions, or any reason other than the possible long-
term consequences of enzyme induction, were excluded.
The discontinuation group consisted of 2 subgroups: (1)
conversion from CBZ to a newer AED or (2) slow with-
drawal of CBZ without conversion to any other AED.
Patients who preferred to continue on CBZ were designated
as a control group for comparison with those undergoing
CBZ discontinuation. The decisions concerning discontinu-
ation were made purely on clinical grounds. In all cases, an
individual therapeutic plan was devised by the treating
epileptologist for the patient0s benefit. The rate of initiation
of therapy with the new AED and tapering off from CBZ
were pursued at the discretion of the treating epileptologist
and were individualized for each patient. The minimum tar-
get dose for the new AED was 800 mg daily for eslicar-
bazepine acetate, 200 mg daily for lacosamide, 1,000 mg
daily for levetiracetam, and 900 mg for gabapentin. We
retrospectively reviewed patient backgrounds, comorbidi-
ties, current and previous AED use, and seizure frequency
from the patient records. Refractory epilepsy was qualified
as having persistent seizures after trials with at least 2
AEDs at maximally tolerated doses (sequentially or in
combination therapy). The use of other potent-inducing
AEDs (phenytoin, primidone, and phenobarbital) is extre-
mely limited in our district and therefore was not included
in the current study.
In our institutions, patients who are established on EI
AEDs are regularly screened for associated long-term prob-
lems including osteoporosis, hyperlipidemia, and sexual
dysfunction. As a part of this process, we measure the fol-
lowing serum variables: SHBG, free testosterone for male
patients, 25-hydroxyvitamin D, total cholesterol, low-den-
sity lipoprotein (LDL), high-density lipoprotein (HDL), and
triglycerides. Among the women with epilepsy, sex hor-
mone profiles are not routinely measured due to compli-
cated interpretations with respect to the menstrual cycle. In
the case of CBZ discontinuation, control blood samples
were obtained at least 3 months after the last dose of CBZ in
order to observe the possible improvement in laboratory
parameters after de-induction. A 3-month timespan was
designated to ensure sufficient time for complete de-induc-
tion of the CYP450 system. In case of CBZ continuation,
blood samples were controlled regularly as a part of the clin-
ical routine. The design of the study entailed each patient
having blood drawn after a minimum of 12 hours of fasting
Key Points
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being treated with inducing AEDs should be switched
to noninducing AEDs
• A significant decrease in serum levels of TC, LDL,
HDL, and SHBG and a significant increase in free
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ation group compared with those who continued with
CBZ
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CBZ to a noninducing AED might be worthy of con-
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on 2 occasions: first at baseline, while taking CBZ; a second
time at 3 months after the last dose of CBZ.
Given the drug interactions between CBZ and statins, the
lipid analyses were performed with exclusion of the statin
users.
Seizure outcome was established for 12 months before
and for the 6 months after baseline. We defined seizure out-
come as either (1) having no seizures for 6 months, which
signified that the patient was seizure-free; or (2) having
experienced a seizure on a therapeutic dose of their AED
during the 6-month period, which indicated the patient was
not seizure-free. Isolated auras were not considered in this
assessment. We also excluded seizures occurring during the
titration period of the new AED.
Descriptive statistics (means and ranges [min to max] or
frequencies and proportions) were utilized to summarize
patients’ characteristics at baseline. Changes in serum sam-
ples were calculated as the difference between the end of
the follow-up and baseline and were reported as means and
standard deviations. We combined 5 serum samples (HDL,
LDL, triglycerides, SHBG, and vitamin D) to evaluate their
overall significance in patients. To combine values from
these 5 different scaled variables, we first standardized each
of them, that is, rescaled them to have a mean of zero and a
standard deviation one. The value of the standardized vari-
able (also called z-score) represents its distance from the
mean in standard deviation units. For example, a standard-
ized value of 0.5 indicates that the value is half a standard
deviation below the mean. Thus, a positive value of the sum
of 5 standardized variables (z-sum) indicates that the value
is above the mean of the z-sum. Before summation, we
changed the sign for variables LDL, triglycerides, and
SHBG in order to code all 5 variables in same order, that is,
large positive value indicates a “better situation” for all
variables.
Chi-square test was used to analyze differences between
groups and categorical variables, this being based on the
assumption of normality; Student’s t-test or Mann-Whitney
U-test was used for continuous variables. Binary logistic
regression analysis was used to estimate the association
between groups and seizure recurrence at 6 months after
baseline. No essential changes in the estimate of group vari-
able were found after adjustments for age, gender, and the
number of prior AEDs and therefore only results from unad-
justed models were reported. After fitting logistic regression
models, predicted probabilities for seizure recurrence
6 months after baseline were calculated by converting to
odds.
All analyses were conducted using Stata statistical soft-
ware version 13.1 (StataCorp, College Station, Texas,
U.S.A.). For all statistical tests, p-value <0.05 was consid-
ered statistically significant.
This was an observational, noninterventional retrospec-
tive study, which does not require ethics committee
approval according to Finnish Law on Research. Access to
patient records was based on a decision made by the Head
of Science Centre, Tampere University Hospital Research
and Innovation Services, Science Center.
Results
Of the 58 patients participating in the study, 24 decided to
continue with CBZ, 10 were withdrawn (7 of them seizure-
free) from CBZ without switching to some other AED, and
24 (13 of them seizure-free) were converted from CBZ to
some other AED (8 to eslicarbazepine acetate, 8 to lacosa-
mide, 7 to levetiracetam, and one to gabapentin). The main
reasons affecting individual decisions to continue with CBZ
were as follows; 11 were anxious that there would be sei-
zure-relapse, 7 were afraid of losing their job and/or driver0s
license should a seizure occur, 2 were not concerned about
the long-term effects of EI, with the final 4 subjects deciding
for reasons best to known themselves.
The baseline data for all patients appear in Table 1. There
were significant differences between the groups with
respect to seizure freedom and mean free testosterone
levels. Recurrent seizures were more frequent, and the
testosterone level was lower in the discontinuation group at
baseline compared to continuation group. The time between
the first and second blood samplings in these patients ranged
from 91 to 334 days (mean 141 days).
Compared to those who continued the CBZ treatment,
patients in the CBZ discontinuation group exhibited signifi-
cant decreases in serum total cholesterol (16%), HDL
(11%), LDL (18%), and SHBG (18%) concentrations
(Table 2.) In men, the free testosterone level was signifi-
cantly increased (39%) in the CBZ discontinuation group
compared to those who continued with CBZ medication.
There were no significant changes in the serum concentra-
tions of triglyceride and vitamin D.
Eslicarbazepine acetate might itself have some impact
on lipids, or perhaps other serologic markers. Therefore,
we re-analyzed the data regarding all the serologic mark-
ers after exclusion of those who were switched to eslicar-
bazepine acetate. The results remained unchanged after
exclusion (data not shown). Two patients had a sporadic
seizure during the titration period of the new drug. In con-
trast, none had withdrawal seizures due to tapering of the
CBZ medication. Data from these seizures are not
included here. Table 3 demonstrates unadjusted odds
ratios for the various subgroups relative to their seizure
status at baseline. The logistic regression model was
adjusted for covariates (age, gender, and number of prior
AEDs), but this did not produce results that differed mark-
edly from those obtained with the unadjusted model (data
not shown). Table 4 presents probabilities for seizure
recurrence 6 months after baseline in the various sub-
groups of previously seizure-free patients. Probabilities
are based on calculations made from the results of the
logistic regression model (Table 3).
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Discussion
The major feature of current study is the systematic
assessment on the seizure outcome of CBZ discontinuation
in various subgroups. In addition, we show here that CBZ
discontinuation produces a broad spectrum of significant
changes in serum concentrations of total cholesterol, HDL,
LDL, SHBG, and testosterone, whereas previous studies
have focused on single metabolic pathways. Despite the rel-
atively modest sample size, the significance of the findings
attests to the robust nature of the effect. The overall conse-
quence of these changes would be expected to result in a
considerable decline in the risk for ischemic vascular dis-
ease and sexual dysfunction in men.
In the current study, approximately 40% of the patients
were ultimately not willing to discontinue CBZ even though
they had initially expressed acquiescence toward an evalua-
tion of metabolic side-effects related to CBZ. Most patients
had been seizure-free with CBZ for decades without experi-
encing any noticeable side effects. On the other hand, aging
is the most important risk factor for vascular events. How-
ever, a significant proportion of patients decided to continue
CBZ despite their appreciation of the possible risks related
to the long-term effects of EI. The importance of good com-
munication between patient and treating physician is under-
scored in these situations.
There were some differences in the baseline characteris-
tics of the study patients relative to CBZ status at baseline
(continuation vs discontinuation). The proportion of sei-
zure-free patients was significantly higher in those who con-
tinued CBZ and who were anxious of the possibility of the
re-appearance of seizures in these currently seizure-free
subjects. The percentage of free testosterone was lower in
the CBZ discontinuation group, suggesting that especially
men with low testosterone levels might be more willing to
end CBZ medication in comparison with their counterparts
with normal testosterone levels.
The inclusion of a control group in our study has added an
important methodologic feature missing from all previous
outcome investigations, with 2 exceptions done by the same
group.16,17 However, in the study by Wang et al.,16 all
switched patients were initially taking phenytoin or CBZ,
whereas the controls were being treated with a diverse group
of 10 different AEDs. We compared the patients who dis-
continued CBZ to those taking CBZ who continued taking
CBZ.
One of the major features of the current study is of practi-
cal significance because we were able to calculate probabili-
ties for seizure recurrence among various subgroups
(Table 4). The recurrence rate after CBZ withdrawal
resulted in an approximately 24 percentage point incremen-
tal additional risk of seizure recurrence. Similarly, convert-
ing CBZ to another AED in seizure-free patients resulted in
an 11 percentage point additional risk of recurrent seizures,
which is in line with recent study.17 We also calculated the
odds of seizure recurrence in seizure-free patients, but the
absolute differences might be more interesting from the
clinician’s perspective.
Most of the epidemiological data demonstrate that
patients with epilepsy have an increased risk of developing
cardiovascular and cerebrovascular disease compared to the
general population.18–22 In addition, carotid media intima
thickness is significantly increased in patients with epilepsy,
particularly among those taking CBZ.23 Furthermore, Sil-
lanp€a€a et al.24 conducted a population-based cohort study
and demonstrated that there was a striking increase in mag-
netic resonance imaging (MRI) abnormalities related to
cerebrovascular disease in patients with epilepsy compared
to healthy controls at the age of 45 years. Following an
Table 1. Baseline characteristics of the study patients
CBZ status at baseline
p-valueContinuation Discontinuation
N 24 34
Age in years (range) 52.6 (25–69) 49.1 (29–78) 0.29a
Female (%) 13 (54.2) 19 (55.9) 0.90b
Statin use (%) 2 (8.3) 5 (14.7) 0.46b
Number of prior
AEDs (%)
0.11b
0 10 (41.7) 13 (38.2)
1–2 9 (37.5) 6 (17.7)
3+ 5 (20.8) 15 (44.1)
Refractory (%) 9 (37.5) 15 (44.1) 0.61b
Number of concomitant
AEDs (%)
0.62b
0 12 (50.0) 15 (44.1)
1 7 (29.2) 14 (41.2)
2–3 5 (20.8) 5 (14.7)
Duration of epilepsy,
years (range)
34.4 (2–53) 30.3 (1–62) 0.32a
Duration of CBZ,
years (range)
29.0 (2–48) 23.7 (1–49) 0.14a
Daily dose of CBZ,
mg (range)
810 (400–1500) 750 (400–1600) 0.47a
Seizure free (%) 21 (87.5) 20 (58.8) 0.018b
Total cholesterol,
mM (SD)
5.7 (1.2) 5.9 (1.3) 0.59a
HDL, mM (SD) 1.8 (0.6) 2.0 (0.6) 0.25a
LDL, mM (SD) 3.6 (1.0) 3.7 (1.0) 0.72a
Triglyceride, mM (SD) 1.3 (0.8) 1.1 (0.6) 0.65c
SHBG, nM (SD) 115.5 (87.1) 100.4 (48.2) 0.97c
Free testosterone,
pM (SD)d
212.8 (73.8) 156.9 (57.5) 0.046c
Vitamin D, nM (SD) 80.2 (34.4) 78.1 (35.7) 0.83a
z-score sume 0.36 (2.66) 0.25 (2.01) 0.32a
AEDs, antiepileptic drugs; CBZ, carbamazepine; HDL, high-density lipopro-
tein; LDL, low-density lipoprotein; SD, standard deviation, SHBG, sex hormone
–binding globulin.
aStudent’s t-test.
bChi-square test.
cMann-Whitney U-test.
dn = 26 (men only).
eThe sum of 5 variables (z-sum) was calculated so that the greater value of z-
sum corresponds to better total situation.
Epilepsia Open, 3(3):340–347, 2018
doi: 10.1002/epi4.12227
343
Discontinuation of Carbamazepine
extensive meta-analysis, Lossius et al.25 concluded that a
decrease in LDL of 0.51 mM, similar to the decline detected
in our patients, could reduce overall mortality by 5 percent-
age points and cardiovascular mortality by 11%.26 Based on
the above findings, atherosclerotic vascular disease appears
to be a genuine risk in the epileptic population. However,
contradictory data do exist.27–30
We observed that there was a decrease in serum con-
centrations of total cholesterol, HDL, and LDL following
discontinuation of CBZ. Furthermore, there was a small,
statistically insignificant, decline in triglyceride levels
seen after CBZ discontinuation. These results are rather
similar to those seen when patients were either switched
from CBZ to some other AED or CBZ was with-
drawn.9,10,18,25 The declines in HDL are likely to be more
than compensated by the negative effects on pro-
atherogenic markers.11 Some variability was seen in the
CBZ continuation group, presumably reflecting the inher-
ent fluctuations in these parameters.
Most statins are extensively metabolized by the CYP sys-
tem and there would be expected to reduce serum levels of
these drugs in the presence of an enzyme inducer.15,18 How-
ever, patients taking statins had been excluded from all pre-
vious studies investigating this topic. In the current study,
some of the patients receiving statins displayed moderate
declines in the lipid profile, others exhibited rather major
declines, for example, 4.5 mM total cholesterol or 3.7 mM
LDL (Fig. 1). Although the number of patients with statins
was low and caution is necessary when considering the clin-
ical implications of this finding, one might speculate that
patients receiving statin therapy should avoid CBZ
treatment.
Table 3. Odds of seizure recurrence 6 months after baseline, among various subgroups relative to seizure status at
baseline (seizure-free or not seizure-free)
Comparison Odds ratio 95% CI p-value
Seizure-free patients at baseline, CBZ discontinue versus continue (n = 41) 5.00 0.51–49.3 0.17
Seizure-free patients at baseline, CBZ withdrawal versus continue (n = 28) 8.00 0.60–106.9 0.12
Seizure-free patients at baseline, CBZ switch to other AED versus continue (n = 34) 3.64 0.30–44.8 0.31
AED, antiepileptic drug; CBZ, carbamazepine; CI, confidence interval.
Table 4. Probabilities for seizure recurrence 6 months after baseline among various subgroups relative to seizure
status at baseline (seizure-free or not-seizure-free)
Comparison Seizure recurrence probabilities Difference
Seizure-free patients at baseline, CBZ discontinue versus continue (n = 41) 20.0% versus 4.8% 15.2 PP
Seizure-free patients at baseline, CBZ withdrawal versus continue (n = 28) 28.6% versus 4.8% 23.8 PP
Seizure-free patients at baseline, CBZ switch to other AED versus continue (n = 34) 15.4% versus 4.8% 10.6 PP
AED, antiepileptic drug; CBZ, carbamazepine; PP, percentage point.
Table 2. Laboratory data after baseline (sampling 2) and comparison of laboratory parameters between sampling one
and sampling two. Statin users were excluded from the lipid analyses
CBZ status at baseline Change from sampling 1 to sampling 2
Continue (n = 24) Discontinue (n = 34) p-value Continue (n = 24) Discontinue (n = 34) p-value
TC, mM (SD)c 5.8 (1.2) 5.1 (1.0) 0.033a 0.05 (0.51) 0.84 (0.78) <0.001a
HDL, mM (SD)c 1.9 (0.7) 1.8 (0.5) 0.70a 0.02 (0.16) 0.21 (0.34) 0.004a
LDL, mM (SD)c 3.5 (1.1) 3.1 (0.9) 0.18a 0.05 (0.64) 0.64 (0.90) 0.006a
Triglyceride, mM (SD)c 1.18 (0.75) 0.94 (0.40) 0.41b 0.06 (0.32) 0.14 (0.42) 0.13b
SHBG, nM (SD) 124.7 (88.8) 82.1 (40.3) 0.042b 9.1 (18.0) 18.4 (39.9) <0.001b
FT, pM (SD)d 212.9 (80.2) 218.1 (93.6) 0.92b 0.09 (22.5) 61.2 (91.8) 0.017b
Vitamin D, nM (SD) 80.3 (31.3) 81.4 (27.2) 0.89a 0.1 (19.2) 3.3 (22.4) 0.58a
z-score sume 0.84 (2.84) 0.59 (2.06) 0.030a 0.48 (1.65) 0.34 (1.61) 0.064a
FT, free testosterone; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation; SHBG, sex hormone–binding globulin; TC, total
cholesterol.
aStudent’s t-test.
bMann-Whitney U-test.
cn = 51 (statin users excluded).
dn = 26 (men only).
eThe sum of 5 variables (z-sum) was calculated so that the greater value of z-sum corresponds to better total situation.
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Figure 1.
Change in laboratory parameters in patients who continued with CBZ and in those with CBZ discontinuation. Each bar shows the abso-
lute change in the laboratory parameter between the first and second samplings for individual subjects, with 24 patients who continued
CBZ shown in white on the left, and the 34 patients who discontinued CBZ in gray on the right. A black bar indicates a statin user.
Epilepsia Open ILAE
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We detected a significant decrease in SHBG levels in
both genders following CBZ discontinuation. In addition,
there was a significant increase in the free testosterone level
in men after CBZ discontinuation. This corresponds well
with clinical experience that some men enjoy improvements
in sexual function after CBZ discontinuation. Unfortu-
nately, standardized sexual function questionnaires are not
routinely used in our institutions, so it was not possible to
investigate whether the improvements in serum concentra-
tions of SHBG and free testosterone correlated with recov-
ery from sexual dysfunction. However, biochemical
abnormalities are clearly evident in men, and these might
have a real impact on patient well-being. The design of our
study meant that we were not able to assess the sex hormone
profiles of females as it is not convenient in clinical practice
to request the patient to come to the clinic to provide a blood
sample at a fixed time point relative to her menstrual cycle.
Unexpectedly, discontinuation of CBZ, however, was not
associated with any increase in serum vitamin D concentra-
tions. Several factors might be speculated to account for this
phenomenon. First, extensive variability was also seen in
the CBZ continuation group in vitamin D levels, which
might be related to seasonal changes of sun exposure with
respect to the time of year. Second, vitamin D supplements
are prescription-free and widely used in Finland. In the
northern hemisphere at latitudes greater than around 40°N
(north of Barcelona), sunlight is not strong enough to trigger
the synthesis of vitamin D in the skin from October to
March. Anecdotally, vitamin D levels seemed to be elevated
particularly in those patients with statin co-medication in
the CBZ discontinuation group (Fig. 1), which might indi-
cate that statins may increase vitamin D concentrations.31
As far as we are aware, no previous study has reported
such a comprehensive laboratory panel related to enzyme-
inducing (or EI) AEDs. This pattern of laboratory tests was
found useful in helping the clinician to estimate the overall
effects of EI in the individual patient. Furthermore, the
numeric parameters may highlight the long-term conse-
quences of EI to the patient in a more concrete manner and
assist the patient to decide for her/himself whether to con-
tinue with CBZ therapy.
Some points must be kept in mind when drawing conclu-
sions from our study. This was a retrospective study, not a
prospective randomized controlled trial, complicating the
comparability of patients in the different groups. However,
this clinical question could not be adequately answered in a
double-blind randomized study. One potential ascertain-
ment bias might have affected the results: those who
switched may have already had some notion that they had a
problem (e.g., with bones or cholesterol), or a family history
of problems, to make them concerned. Moreover, because
the seizure data was gathered only from the previous year,
we were unable to eliminate the possibility of remitting-
relapsing pattern, which is believed to be present in up to
16% of patients with epilepsy, that is, the patients fluctuate
between periods of seizure freedom and recurrence.32 Sam-
ple size might be represented as a limitation for seizure out-
comes, but our results are similar to the prior 2 studies,16,17
suggesting that this is not truly an issue. Furthermore, we
were unable to study patients starting to receive CBZ ther-
apy because this is not compatible with our daily clinical
practice. Finally, we did not account for other factors that
might influence the changes in laboratory parameters, such
as body weight, diet, exercise, or smoking habits.
In conclusion, we believe that the clinical implications of
the current study are considerable for the general health of
patients with epilepsy. With regard to the potential for
chronic adverse effects related to EI, the practice of switch-
ing CBZ patients to noninducing AED might be worth con-
sideration. CBZ is responsible for an elevation in the lipid
profile, alterations in male reproductive function, and
potential drug interactions (especially with statins). There-
fore, the use of CBZ is problematic, particularly in post-
stroke epilepsy and in patients with an increased risk of
vascular disease. On the other hand, one cannot state that all
CBZ should be switched to another non-EI AED; for exam-
ple, if the patient has achieved seizure-freedom but is subse-
quently found to have side effects on important metabolic
pathways, there is nonetheless a real risk of seizure recur-
rence if he/she should be switched to some other AED. All
of these challenges might be avoided by assigning the
appropriate drug in the first place with respect to the latest
expert opinion on treatment of epilepsy, which compared to
earlier surveys, highlights a move away from CBZ as the
drug of choice.33
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